Ford Motor Company vs ResMed Inc. — how do they compare? Ford Motor Company trades at $12.18 (market cap $48.85B), while ResMed Inc. trades at $229.22 (market cap $31.89B). The key difference: Ford Motor Company is the larger of the two by market cap, and Ford Motor Company pays the higher dividend (4.9%). Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 104 Days and ResMed Inc. for 51 Days on average.
| F | RMD | |
|---|---|---|
Market Cap | $48.85B | $31.89B |
Volume | 57,748,965 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $277.88 |
52-Week Low | $11.21 | $182.82 |
Typical Hold Time | 104 Days | 51 Days |
Enterprise Value | $180.81B | $31.24B |
Dividend Yield | 4.9% | 1.16% |
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.125, down 1.22% on the day, amid a challenging quarter with a 6.6% sales decline reported for Q3 2026 (Reuters, 2026-10-02). The stock shows a bearish technical signal, with moving averages indicating a downtrend. Fundamentally, the company reported a net loss of $8.18 billion for 2025, with negative profit margins and ROE, though operating cash flow remains strong at $21.28 billion. Recent news highlights supplier disruptions affecting F-150 production and a strategic shift toward hybrids.
The outlook for Ford is mixed, with analyst consensus leaning toward a 'Hold' (48.93% of ratings) and a price target of $15.90 suggesting potential upside. Key opportunities include the growing hybrid segment and strong commercial division, while risks involve ongoing sales volatility, high debt levels, and competitive pressures from Asian automakers. Investors should weigh the company's cash flow strength against profitability challenges and market share losses.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →